1. Cells of the human myelomonocytic line RC-2A synthesize tissue factor-like procoagulant and urokinase-type plasminogen activator.
- Author
-
Karhumäki E, Saravo L, and Helin H
- Subjects
- Cell Line, Concanavalin A pharmacology, Factor VII pharmacology, Glycoproteins metabolism, Humans, Immunoenzyme Techniques, Phytohemagglutinins pharmacology, Plasminogen Inactivators, Tetradecanoylphorbol Acetate pharmacology, Blood Coagulation Factors biosynthesis, Granulocytes metabolism, Macrophages metabolism, Monocytes metabolism, Urokinase-Type Plasminogen Activator biosynthesis
- Abstract
Cells of the myelomonocytic leukemia cell line RC-2A were studied for their ability to synthesize clotting-promoting and fibrinolytic factors. The cells were observed to generate procoagulant activity (PCA) in readily measurable quantities. Incubation of RC-2A cells with phorbol myristate acetate (PMA; 3 ng/ml) or phytohemagglutinin (PHA, 10 micrograms/ml) for 18 h resulted in a 4-5-fold increase in PCA relative to unstimulated control. The PCA of RC-2A cells was tissue factor-like in that it was dependent on factor VII but not on factors VIII or IX. RC-2A cells also produced plasminogen activator (PA). Secreted PA was approximately 70% of the PA of an identical number of human monocyte-derived macrophages; fresh isolated monocytes synthesized virtually no PA. Compared to macrophages, RC-2A cells secreted less or no PA-inhibitors. Lysates of RC-2A cells contained over three times more PA than lysed macrophages. Stimulation of the cells with lectins (PHA, concanavalin A) or PMA was followed by a modest (2-3-fold) increase in PA. Enzyme immunoassay with antibodies to urokinase (u-PA) or tissue-type PA (t-PA) identified the RC-2A plasminogen activator as being of urokinase type.
- Published
- 1987
- Full Text
- View/download PDF